Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Knee Degenerative Osteoarthritis - Trial NCT05917028
Access comprehensive clinical trial information for NCT05917028 through Pure Global AI's free database. This phase not specified trial is sponsored by Next Biomedical Co., Ltd. and is currently Not yet recruiting. The study focuses on Osteoarthritis. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Next Biomedical Co., Ltd.
Timeline & Enrollment
N/A
Jul 01, 2023
Dec 01, 2025
Primary Outcome
Rate of WOMAC Score Reduction,Rate of VAS Score (patient pain intensity) Reduction
Summary
Among knee degenerative osteoarthritis patients aged 50 or older, it will prove the
 therapeutic effect and safety of Nexsphere-F embolization for patients who need additional
 treatment because pain is not controlled even if conventional treatments are taken.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05917028
Device Trial